YOLFTbeta
Annexin Pharmaceuticals AB

Annexin Pharmaceuticals AB

ANNX · ST · Healthcare / Biotechnology

9.04SEK+0.10 (+1.12%)

Price History

Full chart

Market Stats

Previous Close8.94
Open8.62
Day Range8.32 – 9.04
52-Week Range8.54 – 29.80
Volume13.31K
Market Cap79.86M
P/E (TTM)0.00
Forward P/E0.00
EPS-5.96
Dividend Yield0.00%
Beta0.31
50-Day Avg12.18
200-Day Avg14.07

About

Annexin Pharmaceuticals AB (publ), a clinical stage biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases. It develops ANXV, a human recombinant protein and Annexin A5, natural protein that protects and repairs cells, as well as counteract unwanted inflammatory and immune cell reactions that is in phase 2 clinical phase for the treatment of ophthalmology, oncology, sickle cell disease, and cardiovascular disease. Annexin Pharmaceuticals AB (publ) was incorporated in 2014 and is based in Stockholm, Sweden.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Anders Haegerstrand M.D., Ph.D.
  • Employees4
  • HeadquartersKammakargatan 48, Stockholm, Sweden, 111 60, Sweden
  • Websitehttps://annexinpharma.se

Leadership

  • Dr. Anders Haegerstrand M.D., Ph.D.Chief Executive Officer · b. 1961
  • Ms. Susanne AnderssonChief Financial Officer · b. 1971
  • Ms. Susan SuchdevChief Operating Officer · b. 1972
  • Dr. Anna Frostegård M.D., Ph.D.Chief Scientific & Medical Officer · b. 1973
  • Dr. Mario Fsadni L.L.M., M.Sc.Therapeutic Area Head of Ophthalmology

Financials

Income Statement

Currency: SEK2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue--0000000000
Cost of Revenue380.16K499.70K75.36K477.00K193.00K193.00K193.00K192.00K193.00K193.00K193.00K48.00K
Gross Profit-380.00K-500.00K-75.36K-477.00K-193.00K-193.00K-193.00K-192.00K-193.00K-193.00K-193.00K-48.00K
Operating Expense1.01M4.53M9.71M30.38M28.51M28.14M43.54M51.04M40.53M43.98M50.29M36.27M
Operating Income-1.39M-5.03M-9.78M-30.85M-28.70M-28.33M-43.74M-51.23M-40.72M-44.18M-50.48M-36.31M
EBITDA115.60K-4.98M-9.71M-30.38M-28.51M-28.33M-43.74M-50.28M-40.72M-43.86M-50.20M-36.84M
Net Income-1.39M-5.03M-9.83M-30.93M-28.85M-28.39M-44.74M-52.14M-40.73M-44.05M-50.25M-36.89M
R&D--9.18M24.14M20.40M21.38M33.64M42.13M28.37M36.02M40.81M26.24M
Interest Expense-3.00K47.00K75.00K147.00K33.00K503.00K1.86M2.00K104.00K53.00K0

Balance Sheet

Currency: SEK2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets3.69M3.15M23.46M30.85M46.04M16.04M25.16M52.79M36.68M26.76M19.04M30.16M
Total Liabilities981.14K3.28M7.88M6.41M6.19M4.55M4.52M6.06M6.53M7.95M5.32M5.22M
Total Equity2.71M-137.00K15.57M24.44M39.85M11.49M20.64M46.73M30.15M18.81M13.71M24.93M
Cash1.83M781.00K14.45M14.76M30.22M4.26M18.13M49.48M31.11M21.41M16.34M27.39M
Total Debt700.00K1.00M979.17K729.00K479.00K227.00K------
Net Debt-1.13M219.00K-13.47M-14.03M-29.74M-4.04M-18.13M-49.48M-31.11M-21.41M-16.34M-27.39M

Cash Flow

Currency: SEK2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow--5.01M-9.95M-39.08M-28.50M-25.73M-39.20M-45.02M-41.16M-43.40M-50.23M-36.92M
Investing Cash Flow--207.00K-149.00K-149.00K-50.00K-96.00K-96.00K-260.00K-260.00K96.00K0-129.00K
Financing Cash Flow-4.17M23.62M39.54M44.01M-229.00K53.16M76.37M23.06M33.61M45.15M48.11M
Capital Expenditure0207.00K0149.00K50.00K000043.40M0129.00K
Free Cash Flow--5.22M-9.95M-39.23M-28.55M-25.73M-39.20M-45.02M-41.16M-43.40M-50.23M-37.05M
FCF to OCF-104.13%100.00%100.38%100.18%100.00%100.00%100.00%100.00%100.00%100.00%100.35%

Earnings

Report DateJun 30, 2017Sep 30, 2017Jan 31, 2018Apr 24, 2018Aug 20, 2018Oct 31, 2018Jan 31, 2019May 2, 2019Aug 22, 2019Oct 31, 2019Jan 28, 2020May 7, 2020Aug 21, 2020Oct 29, 2020Feb 4, 2021May 6, 2021Aug 19, 2021Nov 30, 2021Feb 3, 2022May 30, 2022Aug 23, 2022Nov 3, 2022Feb 7, 2023May 17, 2023Aug 3, 2023Oct 18, 2023Feb 9, 2024Apr 12, 2024Jul 18, 2024Oct 17, 2024Feb 6, 2025May 14, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate-------------------------------------
EPS Actual-55.23-20.61-1.14-0.90-0.56-0.16-0.24-0.18-0.20-0.22-0.34-0.21-0.16-0.12-0.21-0.24-0.11-0.09-0.15-0.07-0.08-0.06-0.07-0.06-0.05-0.07-0.09-0.04-0.04-2.00-2.26-1.48-1.19-1.38-1.47-1.46-1.61
Surprise-------------------------------------
Timing--Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-market-----

Key Statistics & Ratios

Market Cap79.86M
Enterprise Value81.04M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book34.22
EPS-5.96
Book Value0.357
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-40.90M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-177.52%
Return on Assets-89.98%
Shares Outstanding8.72M
Shares Float2.22M
Beta0.31
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • May 28, 20251:100